Loading...
Caspofungin, an echinocandin recently approved for patients with invasive aspergillosis refractory to or intolerant of standard therapy, inhibits synthesis of 1,3-β-D-glucan, a component of fungal cell walls. The pharmacokinetics of this new antifungal were investigated in several single- and multiple-dose studies that enrolled a total of 98 healthy men. One-hour intravenous infusions of 15 mg, 35 mg, 50 mg, or 70 mg were administered, daily for 2 or 3 weeks in the multiple-dose studies. The goal was to achieve a mean plasma concentration >1 µg/mL, a level that inhibits 90% of clinically relevant candida species.
In the single-dose studies, caspofungin's distribution phase was short, and elimination half-life was 9 to 10 hours. At the higher…